« Back
Home /
Etripamil

Etripamil

Manufacturer	MedChem Express
Category	Inhibitors
Type	Inhibitors
Specific against	other
Amount	10mM*1mL
Item no.	HY-17611-10mM*1mL
CASRN	1593673-23-4
Available
Product Description	Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist, can be used for the research of Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells.
StorageTemperature	Pure form -20°C 3 years, 4°C 2 years; In solvent -80°C 6 months, -20°C 1 month
Applications	COVID-19-immunoregulation
Formula	C27H36N2O4
References	[1].Stambler BS, et al. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31; 72(5):489-497. \| [2].Milestone Pharmaceuticals Announces USAN Approval of Generic Name “Etripamil” for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia.
MolecularWeight	452.59
Research Area	Cardiovascular Disease
Solubility	Ethanol : 120 mg/mL (265.14 mM; Need ultrasonic)
Target	Calcium Channel
Isoform	L-type calcium channel
Pathway	Membrane Transporter/Ion Channel; Neuronal Signaling

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 10mM*1mL

available

Delivery expected until 4/13/2023

Compare

Add to wishlist

Recommend by mail

Request delivery time

Ask a technical question